Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Endocrine 2Thoracic 1Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 233Head and Neck Neoplasms 150Squamous Cell Carcinoma of Head and Neck 136Stomach Neoplasms 117Lung Neoplasms 109Esophageal Neoplasms 90Uterine Cervical Neoplasms 72Neoplasms 67Urinary Bladder Neoplasms 56Breast Neoplasms 48Ovarian Neoplasms 46Esophageal Squamous Cell Carcinoma 45Pancreatic Neoplasms 44Small Cell Lung Carcinoma 42Neoplasm Metastasis 40Adenocarcinoma Of Esophagus 38Carcinoma, Squamous Cell 33Carcinoma, Ovarian Epithelial 32Mesothelioma, Malignant 30Parkinson Disease 4, Autosomal Dominant Lewy Body 28Lymphoma 28Adenocarcinoma of Lung 25Sarcoma 24Cholangiocarcinoma 24Nasopharyngeal Carcinoma 22Carcinoma 22Unspecified Adult Solid Tumor, Protocol Specific 21Neuroblastoma 21Gallbladder Neoplasms 21Central Nervous System Neoplasms 21

Interventions

Everolimus 17lutetium Lu 177 dotatate 7Octreotide 7pasireotide 6lanreotide 6gallium Ga 68 dotatate 5Temozolomide 5Sunitinib 5Positron Emission Tomography Computed Tomography 5surufatinib 4pembrolizumab 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neuroendocrine Tumors × Cisplatin × Clear all
NCT02402920 2026-03-10

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Completed
83 enrolled 13 charts
EndocrineNET

Neuroendocrine Tumors

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡